FDA guidance
Accelerated Approval – Expedited Program for Serious Conditions
FDA guidance · Draft · issued Dec 5, 2024
Key facts
| Title | Accelerated Approval – Expedited Program for Serious Conditions |
|---|---|
| Status | Draft |
| Issue date | Dec 5, 2024 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Docket number | FDA-2024-D-2033 |
| Comments close | Feb 4, 2025 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents